The Hypoxia-regulated Ectonucleotidase CD73 is a Host Determinant of HIV Latency
暂无分享,去创建一个
S. Pillai | E. Eugenin | R. Schwarzer | N. Roan | Silvana Valdebenito | H. Sperber | K. Raymond | M. Bouzidi | Tongcui Ma
[1] Xinyue Wang,et al. Decreased CD73+ Double-Negative T Cells and Elevated Level of Soluble CD73 Correlated With and Predicted Poor Immune Reconstitution in HIV-Infected Patients After Antiretroviral Therapy , 2022, Frontiers in Immunology.
[2] Jiyuan Zhang,et al. Reversal of the CD8+ T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways , 2021, Frontiers in Immunology.
[3] W. Greene,et al. Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4+ T cell subsets in vivo , 2021, Cell reports.
[4] W. Greene,et al. Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir , 2020, eLife.
[5] P. Borrow,et al. Hypoxic microenvironment shapes HIV-1 replication and latency , 2020, Communications Biology.
[6] L. Buisseret,et al. The adenosine pathway in immuno-oncology , 2020, Nature Reviews Clinical Oncology.
[7] L. Giudice,et al. HIV efficiently infects T cells from the endometrium and remodels them to promote systemic viral spread , 2020, eLife.
[8] M. Donoso,et al. Platelets from HIV-infected individuals on antiretroviral drug therapy with poor CD4+ T cell recovery can harbor replication-competent HIV despite viral suppression , 2020, Science Translational Medicine.
[9] B. Berkhout,et al. The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like , 2019, Front. Immunol..
[10] Rosa M. Badia,et al. Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab , 2019, Nature Communications.
[11] Yong Wan,et al. CD73: an emerging checkpoint for cancer immunotherapy. , 2019, Immunotherapy.
[12] P. Klenerman,et al. CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype , 2019, Mucosal Immunology.
[13] J. McCune,et al. CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals , 2019, Pathogens & immunity.
[14] R. Cheynier,et al. HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy , 2019, Nature Microbiology.
[15] J. Sosman,et al. CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy , 2019, Nature Communications.
[16] S. Morgello,et al. Identification, Localization, and Quantification of HIV Reservoirs Using Microscopy , 2018, Current protocols in cell biology.
[17] D. Allard,et al. Targeting the CD73-adenosine axis in immuno-oncology. , 2019, Immunology letters.
[18] L. Kats,et al. Targeting Adenosine Receptor Signaling in Cancer Immunotherapy , 2018, International journal of molecular sciences.
[19] R. Apps,et al. Evidence that CD32a does not mark the HIV-1 latent reservoir , 2018, Nature.
[20] O. Sued,et al. Induction of HIF-1α by HIV-1 Infection in CD4+ T Cells Promotes Viral Replication and Drives Extracellular Vesicle-Mediated Inflammation , 2018, mBio.
[21] R. Apps,et al. Evidence that CD32a does not mark the HIV-1 latent reservoir , 2018, Nature.
[22] L. Emens,et al. Targeting adenosine for cancer immunotherapy , 2018, Journal of Immunotherapy for Cancer.
[23] R. Gottardo,et al. CD32+ and PD-1+ Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals , 2018, Journal of Virology.
[24] P. Klenerman,et al. CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA , 2018, Front. Immunol..
[25] S. Eichmüller,et al. Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E , 2018, Front. Immunol..
[26] Ghasem Ghalamfarsa,et al. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer , 2018, Journal of cellular physiology.
[27] Emily B Hanhauser,et al. Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30 , 2018, PLoS pathogens.
[28] L. Su,et al. Regulatory T Cells Contribute to HIV-1 Reservoir Persistence in CD4+ T Cells Through Cyclic Adenosine Monophosphate–Dependent Mechanisms in Humanized Mice In Vivo , 2017, The Journal of infectious diseases.
[29] R. Balderas,et al. CTLA‐4+PD‐1− Memory CD4+ T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy‐Suppressed, SIV‐Infected Rhesus Macaques , 2017, Immunity.
[30] Deborah S. Barkauskas,et al. Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases , 2017, Oncoimmunology.
[31] Y. Lévy,et al. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses , 2017, Nature.
[32] L. Zenewicz,et al. Oxygen Levels and Immunological Studies , 2017, Front. Immunol..
[33] F. Di Virgilio,et al. Extracellular purines, purinergic receptors and tumor growth , 2016, Oncogene.
[34] S. Lewin,et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART , 2016, PLoS pathogens.
[35] L. Antonioli,et al. Anti-CD73 in cancer immunotherapy: awakening new opportunities. , 2016, Trends in cancer.
[36] C. Rinaldo,et al. Critical Role for the Adenosine Pathway in Controlling Simian Immunodeficiency Virus-Related Immune Activation and Inflammation in Gut Mucosal Tissues , 2015, Journal of Virology.
[37] E. Verdin,et al. HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells , 2015, PLoS pathogens.
[38] N. Chomont,et al. HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? , 2015, Journal of virus eradication.
[39] Xin Geng,et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection , 2013, Nature.
[40] Timothy J. Laurent,et al. Dual-color HIV reporters trace a population of latently infected cells and enable their purification. , 2013, Virology.
[41] W. Greene,et al. Calcium/Calcineurin Synergizes with Prostratin to Promote NF-κB Dependent Activation of Latent HIV , 2013, PloS one.
[42] Sarah B. Laskey,et al. Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.
[43] W. Greene,et al. An Integrated Overview of HIV-1 Latency , 2013, Cell.
[44] J. Hauber,et al. Decreased frequency of CD73+CD8+ T cells of HIV‐infected patients correlates with immune activation and T cell exhaustion , 2013, Journal of leukocyte biology.
[45] J. Mellors,et al. CD4+CD73+ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression , 2013, AIDS.
[46] L. Marchionni,et al. High Levels of CD2 Expression Identify HIV-1 Latently Infected Resting Memory CD4+ T Cells in Virally Suppressed Subjects , 2013, Journal of Virology.
[47] E. Vizi,et al. CD39 and CD73 in immunity and inflammation. , 2013, Trends in molecular medicine.
[48] A. K. Kondapi,et al. Involvement of human topoisomerase II isoforms in HIV-1 reverse transcription. , 2013, Archives of biochemistry and biophysics.
[49] J. Dranoff,et al. Activated hepatic stellate cells upregulate transcription of ecto-5'-nucleotidase/CD73 via specific SP1 and SMAD promoter elements. , 2012, American journal of physiology. Gastrointestinal and liver physiology.
[50] W. Greene,et al. A Flexible Model of HIV-1 Latency Permitting Evaluation of Many Primary CD4 T-Cell Reservoirs , 2012, PloS one.
[51] Bin Zhang. CD73 promotes tumor growth and metastasis , 2012, Oncoimmunology.
[52] K. Khalili,et al. Regulation of the HIV-1 promoter by HIF-1α and Vpr proteins , 2011, Virology Journal.
[53] J. Schrader,et al. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. , 2011, American journal of physiology. Cell physiology.
[54] A. Ohta,et al. In vivo T Cell Activation in Lymphoid Tissues is Inhibited in the Oxygen-Poor Microenvironment , 2011, Front. Immun..
[55] O. Delaneau,et al. CD39/Adenosine Pathway Is Involved in AIDS Progression , 2011, PLoS pathogens.
[56] C. Kieda,et al. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia , 2011, Journal of cellular and molecular medicine.
[57] Kenneth W Dunn,et al. A practical guide to evaluating colocalization in biological microscopy. , 2011, American journal of physiology. Cell physiology.
[58] Bin Zhang. CD73: a novel target for cancer immunotherapy. , 2010, Cancer research.
[59] Sergei Nekhai,et al. Regulation of HIV‐1 transcription at 3% versus 21% oxygen concentration , 2009, Journal of cellular physiology.
[60] K. Khalili,et al. Activation of the Oxidative Stress Pathway by HIV-1 Vpr Leads to Induction of Hypoxia-inducible Factor 1α Expression* , 2009, Journal of Biological Chemistry.
[61] J Darbyshire,et al. CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.
[62] E. Verdin,et al. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro , 2003, The EMBO journal.
[63] E. Heist,et al. Protein Kinase A Negatively Modulates the Nuclear Accumulation of NF-ATc1 by Priming for Subsequent Phosphorylation by Glycogen Synthase Kinase-3* , 2002, The Journal of Biological Chemistry.
[64] S. Colgan,et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. , 2002, The Journal of clinical investigation.
[65] S. Jalkanen,et al. The evidence for two opposite, ATP-generating and ATP-consuming, extracellular pathways on endothelial and lymphoid cells. , 2002, The Biochemical journal.
[66] W. Greene,et al. Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy , 2002, Nature Medicine.
[67] M. Sitkovsky,et al. Differential Effects of Physiologically Relevant Hypoxic Conditions on T Lymphocyte Development and Effector Functions , 2001, The Journal of Immunology.
[68] R. Siliciano,et al. Latency and viral persistence in HIV-1 infection. , 2000, The Journal of clinical investigation.
[69] R. Lempicki,et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[70] D. Baltimore,et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. , 1999, Immunity.
[71] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.
[72] S. Harrison,et al. Structure of an IκBα/NF-κB Complex , 1998, Cell.
[73] H. Saito,et al. Hematopoietic transcription factor GATA‐2 activates transcription from HIV‐1 long terminal repeat , 1998, AIDS.
[74] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[75] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[76] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[77] C. Webb,et al. Isolation and characterization of the promoter of the human 5'-nucleotidase (CD73)-encoding gene. , 1995, Gene.
[78] Douglas L. Smith,et al. Any Color You Like , 1994 .
[79] C. Kneitz,et al. Mechanism of MHC class I downregulation in HIV infected cells. , 1992, Immunobiology.